Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT

6 7 月, 2025

One Min Read

12 Views

原文: https://finance.yahoo.com/news/piper-sandler-maintains-buy-rating-081539458.html

Last Update: 6 7 月, 2025

Written By

Other Articles

Previous

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

Next

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

Related Posts

Powerball jackpot soars to $1.3 billion. Here’s what the winner will take home after taxes.

1 Min Read

What is force-placed car insurance, and when do lenders require it?

1 Min Read

Do you need collateral for a personal loan? See when it might help.

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept